[177Lu]PSMA-617 radionuclide therapy shows promise
نویسندگان
چکیده
منابع مشابه
Gene therapy for Parkinson's disease shows promise.
CLINICAL TRIALS NEUROLOGICAL DISEASES ARE AMONG THE MOST INTERESTING APPLICATIONS FOR gene therapy. A er decades of preclinical development, viral vector–based gene transfer has now reached the clinic, and early-stage clinical trials are currently in progress in three areas: congenital blindness and retinal degeneration; the childhood metabolic disorder Bat-ten disease; and the progressive neur...
متن کاملPSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
UNLABELLED Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long tumor retention, the DOTA-conjugated ligand PSMA-617 has low kidney uptake, making it an excellent choice for therapeutic application. We retrospectively report our experience with (177)Lu-PSMA-617-targe...
متن کاملOsteopathic Manipulative Therapy Shows Promise for Improving Postdiskectomy Recovery.
The Journal of the American Osteopathic Association October 2015 | Vol 115 | No. 10 because the change was less than 25%, the cutoff for clinical relevancy. The authors conclude that this finding adds to the building evidence for the safety of cervical spine manipulation with regard to vertebral artery derangement. As a contributor in the past decade to the American Osteopathic Association’s ef...
متن کاملHemophilia B gene therapy in humans shows promise.
1. Nathwani AC, Gray JT, Ng CYC, Zhou J, Spence Y, Waddington SN, Tuddenham EG, Kemball-Cook G, McIntosh J, Boon-Spijker M, Mertens K, Davidoff AM. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Gene Therapy. 2006;107:2653–2661. 2. Nathwani AC, Rosa...
متن کاملPreliminary breast cancer vaccine study shows promise.
A vaccine designed to treat breast cancer has performed surprisingly well in an initial clinical study. In a phase II trial of 186 patients, the vaccine targeting the HER2/neu E75 peptide reduced the risk of recurrence by 50% in 101 breast cancer patients who were clinically disease free after treatment compared with those who were not treated with the vaccine. Immunized patients also had about...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Urology
سال: 2018
ISSN: 1759-4812,1759-4820
DOI: 10.1038/s41585-018-0029-6